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fects or the different site of action on the GABA A /BZD 
receptor complex may account for this deviating pro-
fi le. 
 Copyright © 2005 S. Karger AG, Basel 
 Introduction 
 Saccadic eye movements are controlled by frontal eye 
fi elds, substantia nigra, superior colliculus, pontine re-
ticular formation and cerebellum. These regions contain 
high amounts of GABA A  receptors  [1] . Saccade eye veloc-
ity (SEV) is mediated by the superior colliculus, which is 
under tonic GABAergic control. Studies in primates have 
shown that injection of GABA agonists into the superior 
colliculus induce a selective reduction in SEV whereas 
injection of a GABA antagonist leaves SEV unchanged 
 [2] . Hommer et al.  [3] showed that intravenous adminis-
tration of benzodiazepines leads to a decrease of SEV in 
a dose-dependent manner, accompanied by a decrease in 
plasma cortisol levels and an increase in self-rated seda-
tion and plasma growth hormone. They therefore sug-
gested SEV as a quantifi able and reliable parameter to 
evaluate changes in sensitivity of the GABA A /BZD recep-
tor in humans. Moreover, SEV has also been used as an 
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 Abstract 
 Background: Saccadic eye velocity (SEV) has been shown 
to be a reliable neurophysiological tool for the assess-
ment of   -aminobutyric acid GABA A  receptor sensitivity. 
Administration of benzodiazepines targeting the GABA A  
receptor decreases SEV in healthy volunteers. Tiagabine 
is a new antiepileptic drug which acts via selective block-
ade of GABA reuptake. Therefore, we examined the ef-
fects of tiagabine on saccade parameters.  Methods: SEV 
was analyzed in 8 healthy volunteers before and after 7 
days of tiagabine treatment. Subjects received tiagabine 
in a daily dose of 15 mg. Saccades were measured using 
a noninvasive infrared oculographic device. Amplitude, 
latency, and SEV were analyzed as a function of treat-
ment and target eccentricity.  Results: SEV and saccade 
latency increased with target amplitude. Treatment with 
tiagabine had no signifi cant effect on SEV and saccade 
amplitude. A trend was found for increased latencies af-
ter tiagabine.  Conclusion: In contrast to fi ndings with 
benzodiazepines, tiagabine treatment had no impact on 
SEV in healthy volunteers. The subchronic tolerance ef-
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objective measure of sedation  [4] . Investigations in pa-
tients with panic disorder have shown that these patients 
show a reduced sensitivity of the GABA A /BZD receptor 
to benzodiazepines compared with healthy controls  [5] . 
In patients with premenstrual dysphoric disorder a de-
creased SEV appears to refl ect pathophysiological altera-
tions implicated in this disorder  [6] . 
 Tiagabine is a new antiepileptic compound that exerts 
its anticonvulsant effects via blockade of the GABA trans-
porter I. Tiagabine inhibits GABA reuptake from the syn-
aptic cleft and consequently leads to an increase in 
 GABAergic neurotransmission  [7] . Apart from anticon-
vulsant properties also anxiolytic activity has been noted 
in patients with panic disorder  [8] . 
 To further characterize the impact of tiagabine on 
GABA A  receptor function in humans we investigated the 
effects of tiagabine on SEV assuming that this measure 
may be indicative of GABA A /BZD receptor sensitivity. 
We hypothesized that treatment with tiagabine might de-
crease SEV in healthy subjects. 
 Methods 
 Ten healthy volunteers (7 males, 3 females, mean age 27.6  8 4 
years) were investigated. They were screened for a history of men-
tal or somatic diseases. None of the participants had taken opiates 
or benzodiazepines during 4 weeks before the experimental session, 
as assessed by urine toxicology screening. The protocol was ap-
proved by the local ethics committee of the Medical Department. 
All subjects had given their written informed consent after a com-
plete description of the study. 
 At baseline and after 7 days of tiagabine treatment saccadic ve-
locity was tested at 9.00 o’clock a.m. Tiagabine was administered 
during 7 consecutive days 3 times daily in a daily dose of 15 mg. 
To check the subjects’ compliance to drug intake serum levels of 
tiagabine were determined by high-performance liquid chromatog-
raphy. For the oculomotor test subjects performed a saccade task 
which required them to follow a white target dot (diameter: 3 mm) 
on a dark background of a 17-inch computer monitor as quickly 
and accurately as possible. The distance between the eyes and the 
monitor was 28 cm. Starting from a central fi xation position the 
dot randomly jumped to 7°, 14°, or 21° right or left of the center, 
remained there for 1,200–2,000 ms (random variation) and then 
returned to the center. After a variable period between 1,200 and 
2,000 ms the next target step started. 240 test trials were presented 
after completion of 10 familiarization trials. Generation and timing 
of the visual target was software-controlled (ERTS, BeriSoft Corp.). 
Eye movements were recorded using an infrared pupil-cornea re-
fl ection system (Eye Trac 210, ASL Corp.) and stored (sampling 
frequency: 500 Hz) together with event markers on a personal com-
puter for offl ine analysis. Head movement was strictly discouraged 
by instruction and minimized by a chin and forehead rest. We es-
timated SEV as peak velocity of individual saccades by computing 
mean velocity and multiplying this value by 1.64  [1] . Mean veloc-
ity was computed by dividing the measured amplitude of each sac-
cade by the duration of the respective saccade. Start and end point 
of a saccade were determined by hand and rechecked by an inde-
pendent rater. In addition, amplitudes and latencies of saccades 
were assessed. Only correct saccades, i.e. saccades where the subject 
fi xated the central dot during a 400-ms baseline and when the sac-
cade amplitude showed a gain between 0.7 and 1.1 were used in the 
analyses. For each participant median peak velocities, amplitudes, 
and latencies were then computed separately for each target ampli-
tude in the pre- and post-treatment sessions. These values were 
entered into ANOVAs for repeated measures with Target Ampli-
tude (7°, 14°, 21°) and Treatment (pre- vs. post-) as factors; p  ! 0.05 
was used as the level of signifi cance. Greenhouse-Geisser correc-
tions were applied where necessary. 
 Results 
 Eight out of 10 subjects remained in the analysis (6 
male, 2 female, mean age 28  8 4 years). Two subjects 
were excluded due to technical artifacts. Descriptive re-
sults are shown in  table 1 . There was a signifi cant increase 
in SEV with increasing amplitude [main effect of target 
amplitude: F(2, 14) = 155.0,   = 0.65, p  ! 0.001]. The ef-
fect of tiagabine Treatment (pre- vs. post-) on SEV showed 
a nonsignifi cant trend for higher SEV after treatment 
[F(1, 7) = 4.26, p = 0.078]. There was also a trend for an 
interaction    of    Target   Amplitude    !   Treatment   [F(2,  
14) = 3.39,   = 0.72, p = 0.085]. Paired comparisons re-
vealed that only with 14° targets SEV increased after ti-
Target
amplitude
SEV Saccade amplitude Saccade latency
pre post pre post pre post
7° 187 (19) 191 (17) 6.6 (0.3) 6.5 (0.4) 154 (18) 159 (15)
14° 265 (23) 285 (28) 12.9 (0.6) 12.9 (0.6) 161 (8) 161 (11)
21° 322 (26) 321 (40) 18.8 (0.9) 18.9 (1.1) 167 (10) 167 (11)
Group means and standard deviation (in parentheses) are indicated.
Table 1. SEV (degrees/s), saccade 
amplitude (degrees), and saccade latency 
(ms) for 7°, 14°, and 21° amplitudes at 
baseline (pre) and after 7 days of tiagabine 
treatment (post) in a daily dose of 15 mg
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agabine [t(7) = –3.95, p = 0.006]. To test whether SEV is 
affected by varying saccade amplitudes across time, 
ANOVA was also performed for saccade amplitudes. No 
effect was found for treatment on saccade amplitudes 
[F(1, 7) = 0.01, p = 0.93] nor was there an interaction of 
Treatment  ! Target Amplitude [F(2, 14) = 0.16,   = 0.68, 
p = 0.77]. Saccade latencies showed a signifi cant effect of 
Target Amplitude [F(2, 14) = 6.77,   = 0.65, p = 0.023], 
indicating increasing latencies with increasing eccentric-
ity of targets. Treatment had a marginal effect [F(1, 7) = 
5.36, p = 0.054], which is due to a trend for delayed sac-
cade onset with 7° targets after tiagabine treatment 
[t(7) = –2.27, p = 0.057]. 
 Apart from slight vertigo, dizziness and slight sedation 
in the fi rst 3 days of treatment tiagabine was safe and well 
tolerated by all subjects. None reported any sedation or 
loss of concentration after the treatment period. All sub-
jects reached suffi cient tiagabine plasma levels (mean 126 
 8 11 ng/ml). 
 Discussion 
 In conclusion, we found no effects of treatment with 
the GABA reuptake blocker tiagabine on SEV. After a 7-
day period of treatment with tiagabine 15 mg daily, peak 
SEV remained unchanged. This is in contrast to prior 
fi ndings with benzodiazepines administered to experi-
mental animals and healthy subjects. Hikosaka and Wurtz 
 [2] found a marked reduction of SEV after injection of a 
GABA agonist in the superior colliculus, which is sup-
posed to control SEV. Moreover, studies in healthy sub-
jects showed a reduction of SEV after injection of diaz-
epam  [3] or midazolam  [9] . 
 However, it has to be considered that these studies in-
vestigated changes in SEV only after intravenous injec-
tion of benzodiazepines. In addition, only short-term ef-
fects were assessed. Ball et al.  [10] observed that effects 
of repeated midazolam injections on SEV showed a rela-
tively fast return to baseline within 15–30 min and sug-
gested that this either indicates an acute tolerance to ef-
fects of benzodiazepines or refl ects a redistribution phe-
nomenon. In view of the rapid changes and the absence 
of midazolam metabolites this phenomenon could not be 
explained with benzodiazepine metabolism. In the light 
of these fi ndings, the subchronic administration or toler-
ance effects might explain the lack of infl uence of tiagabi-
ne treatment on SEV in our study. However, van Steve-
ninck et al.  [11] suggested that saccadic eye movement 
parameters reliably refl ect plasma benzodiazepine levels. 
As all subjects in our sample reached suffi cient tiagabine 
plasma levels, bioavailability of the compound cannot 
account for our fi ndings. 
 Moreover, studies investigating the effects of benzodi-
azepine injection after chronic benzodiazepine adminis-
tration in patients with panic disorder showed a striking 
reduction of benzodiazepine receptor sensitivity  [9, 12] 
refl ected by an attenuated reduction of SEV after intra-
venously administered benzodiazepines. One hypothesis 
is a possible decrease in the number of benzodiazepine 
receptors after long-term treatment with benzodiazepines 
 [9] . Therefore, differences in GABA A /BZD receptor den-
sity following benzodiazepine or tiagabine administra-
tion might also be responsible for the lack of change of 
SEV after tiagabine treatment  [9] . 
 However, to our knowledge there is no study investi-
gating the effects of drugs targeting selectively the GABA 
binding site of the GABA A /BZD receptor complex on 
SEV in humans so far. Interestingly, sleep studies showed 
that agonists for the GABA binding site produce a much 
more favorable sleep EEG profi le compared to benzodi-
azepines with no REM suppression, an enhancement of 
slow wave activity during non-REM sleep, and no with-
drawal effects  [13] . Given the fact that there is no report 
of dependency or withdrawal after tiagabine treatment so 
far, it seems possible that there exists a different effect 
profi le of tiagabine on GABA receptor function, and this 
might be refl ected by SEV measures like those presented 
here. 
 Since tiagabine treatment did not affect SEV and since 
there was only a trend for changes in saccadic latency as 
measures of sedation and attention  [4] , advantages of se-
lective GABAergic treatment with tiagabine compared to 
benzodiazepines can be suggested. 
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